Aarti Drugs Share Price
Sector: Biotechnology & Drugs
354.05 +3.35 (0.96%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
350
Today’s High
360.60
52 Week Low
312.50
52 Week High
634.90
355.10 +4.30 (1.23%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
346.60
Today’s High
360.80
52 Week Low
312
52 Week High
635
Key Metrics
- Market Cap (In Cr) 3232.8
- Beta 0.79
- Div. Yield (%) 0.29
- P/B 2.52
- TTM P/E 27.59
- Peg Ratio -1.43
- Sector P/E 26.62
- Open Price 350.55
- Prev Close 350.7
Aarti Drugs Analysis
Price Analysis
-
1 Week-1.86%
-
3 Months-14.42%
-
6 Month-26.1%
-
YTD-23.81%
-
1 Year-29.87%
Risk Meter
- 38% Low risk
- 38% Moderate risk
- 38% Balanced Risk
- 38% High risk
- 38% Extreme risk
Aarti Drugs News
Stocks to Watch: HUL, SBI, Piramal Pharma, Sona BLW, Pidilite Ind, and more
2 min read . 24 Oct 2024Stocks to Watch: Vodafone Idea, BHEL, HDFC Bank, IIFL, Tata Steel and more
2 min read . 23 Sep 2024Aarti Drugs share price rises 12%: To consider buyback proposal on 26 August
2 min read . 22 Aug 2024Aarti Drugs Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 2528.58
- Selling/ General/ Admin Expenses Total
- 193.15
- Depreciation/ Amortization
- 51.45
- Other Operating Expenses Total
- 9.11
- Total Operating Expense
- 2259.01
- Operating Income
- 269.57
- Net Income Before Taxes
- 235.53
- Net Income
- 171.42
- Diluted Normalized EPS
- 18.66
- Period
- 2024
- Total Assets
- 2432.36
- Total Liabilities
- 1150.81
- Total Equity
- 1281.55
- Tangible Book Valueper Share Common Eq
- 135.39
- Period
- 2024
- Cashfrom Operating Activities
- 358.92
- Cashfrom Investing Activities
- -223.65
- Cashfrom Financing Activities
- -136.03
- Net Changein Cash
- -0.76
- Period
- 2023
- Total Revenue
- 2716.05
- Selling/ General/ Admin Expenses Total
- 191.38
- Depreciation/ Amortization
- 50.32
- Other Operating Expenses Total
- 9.14
- Total Operating Expense
- 2456.93
- Operating Income
- 259.13
- Net Income Before Taxes
- 224.18
- Net Income
- 166.31
- Diluted Normalized EPS
- 17.96
- Period
- 2023
- Total Assets
- 2421.4
- Total Liabilities
- 1228.96
- Total Equity
- 1192.43
- Tangible Book Valueper Share Common Eq
- 126.14
- Period
- 2023
- Cashfrom Operating Activities
- 133.32
- Cashfrom Investing Activities
- -163.97
- Cashfrom Financing Activities
- 16.54
- Net Changein Cash
- -14.11
- Period
- 2022
- Total Revenue
- 2488.65
- Selling/ General/ Admin Expenses Total
- 177.01
- Depreciation/ Amortization
- 50.05
- Other Operating Expenses Total
- 7.26
- Total Operating Expense
- 2206.1
- Operating Income
- 282.55
- Net Income Before Taxes
- 269.96
- Net Income
- 205.04
- Diluted Normalized EPS
- 22.14
- Period
- 2022
- Total Assets
- 2207.96
- Total Liabilities
- 1171.6
- Total Equity
- 1036.36
- Tangible Book Valueper Share Common Eq
- 111.9
- Period
- 2022
- Cashfrom Operating Activities
- 69.64
- Cashfrom Investing Activities
- -148.86
- Cashfrom Financing Activities
- 92.03
- Net Changein Cash
- 12.8
- Period
- 2021
- Total Revenue
- 2154.78
- Selling/ General/ Admin Expenses Total
- 165.73
- Depreciation/ Amortization
- 49.88
- Other Operating Expenses Total
- 4.7
- Total Operating Expense
- 1767.33
- Operating Income
- 387.45
- Net Income Before Taxes
- 369.01
- Net Income
- 280.41
- Diluted Normalized EPS
- 30.07
- Period
- 2021
- Total Assets
- 1766.01
- Total Liabilities
- 852.59
- Total Equity
- 913.42
- Tangible Book Valueper Share Common Eq
- 97.98
- Period
- 2021
- Cashfrom Operating Activities
- 154.95
- Cashfrom Investing Activities
- -71.78
- Cashfrom Financing Activities
- -81.13
- Net Changein Cash
- 2.04
- Period
- 2020
- Total Revenue
- 1806.09
- Selling/ General/ Admin Expenses Total
- 144.01
- Depreciation/ Amortization
- 48.75
- Other Operating Expenses Total
- 3.03
- Total Operating Expense
- 1589.33
- Operating Income
- 216.76
- Net Income Before Taxes
- 185.29
- Net Income
- 141.4
- Diluted Normalized EPS
- 14.81
- Period
- 2020
- Total Assets
- 1576.5
- Total Liabilities
- 924.01
- Total Equity
- 652.49
- Tangible Book Valueper Share Common Eq
- 69.85
- Period
- 2020
- Cashfrom Operating Activities
- 250.74
- Cashfrom Investing Activities
- -33.21
- Cashfrom Financing Activities
- -215.41
- Net Changein Cash
- 2.13
- Period
- 2019
- Total Revenue
- 1560.94
- Selling/ General/ Admin Expenses Total
- 109.43
- Depreciation/ Amortization
- 42.56
- Other Operating Expenses Total
- 2.86
- Total Operating Expense
- 1392.59
- Operating Income
- 168.35
- Net Income Before Taxes
- 131.02
- Net Income
- 89.75
- Diluted Normalized EPS
- 9.24
- Period
- 2019
- Total Assets
- 1455.49
- Total Liabilities
- 912.04
- Total Equity
- 543.45
- Tangible Book Valueper Share Common Eq
- 57.3
- Period
- 2019
- Cashfrom Operating Activities
- 143.09
- Cashfrom Investing Activities
- -61.67
- Cashfrom Financing Activities
- -80.07
- Net Changein Cash
- 1.35
- Period
- 2024-12-31
- Total Revenue
- 556.6
- Selling/ General/ Admin Expenses Total
- 27.76
- Depreciation/ Amortization
- 13.8
- Other Operating Expenses Total
- 115.72
- Total Operating Expense
- 508.67
- Operating Income
- 47.93
- Net Income Before Taxes
- 50.76
- Net Income
- 37.04
- Diluted Normalized EPS
- 4.06
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 598.33
- Selling/ General/ Admin Expenses Total
- 26.56
- Depreciation/ Amortization
- 13.72
- Other Operating Expenses Total
- 110.73
- Total Operating Expense
- 545.01
- Operating Income
- 53.32
- Net Income Before Taxes
- 45.88
- Net Income
- 35.01
- Diluted Normalized EPS
- 3.83
- Period
- 2024-09-30
- Total Assets
- 2429.55
- Total Liabilities
- 1152.15
- Total Equity
- 1277.4
- Tangible Book Valueper Share Common Eq
- 139.71
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 168.13
- Cashfrom Investing Activities
- -89.33
- Cashfrom Financing Activities
- -74.2
- Net Changein Cash
- 4.6
- Period
- 2024-06-30
- Total Revenue
- 555.34
- Selling/ General/ Admin Expenses Total
- 26.43
- Depreciation/ Amortization
- 13.38
- Other Operating Expenses Total
- 104.13
- Total Operating Expense
- 503.76
- Operating Income
- 51.58
- Net Income Before Taxes
- 43.98
- Net Income
- 33.24
- Diluted Normalized EPS
- 3.62
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 619.99
- Selling/ General/ Admin Expenses Total
- 25.87
- Depreciation/ Amortization
- 13.58
- Other Operating Expenses Total
- 111.21
- Total Operating Expense
- 547.76
- Operating Income
- 72.22
- Net Income Before Taxes
- 64.18
- Net Income
- 47.31
- Diluted Normalized EPS
- 5.18
- Period
- 2024-03-31
- Total Assets
- 2432.36
- Total Liabilities
- 1150.81
- Total Equity
- 1281.55
- Tangible Book Valueper Share Common Eq
- 135.39
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 358.92
- Cashfrom Investing Activities
- -223.65
- Cashfrom Financing Activities
- -136.03
- Net Changein Cash
- -0.76
- Period
- 2023-12-31
- Total Revenue
- 605.94
- Selling/ General/ Admin Expenses Total
- 25.55
- Depreciation/ Amortization
- 12.66
- Other Operating Expenses Total
- 105.02
- Total Operating Expense
- 548.47
- Operating Income
- 57.47
- Net Income Before Taxes
- 51.55
- Net Income
- 36.67
- Diluted Normalized EPS
- 3.99
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 641.54
- Selling/ General/ Admin Expenses Total
- 25.45
- Depreciation/ Amortization
- 12.61
- Other Operating Expenses Total
- 110.62
- Total Operating Expense
- 577.71
- Operating Income
- 63.83
- Net Income Before Taxes
- 56.27
- Net Income
- 39.6
- Diluted Normalized EPS
- 4.29
- Period
- 2023-09-30
- Total Assets
- 2351.83
- Total Liabilities
- 1142.39
- Total Equity
- 1209.44
- Tangible Book Valueper Share Common Eq
- 131.42
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 218.87
- Cashfrom Investing Activities
- -109.59
- Cashfrom Financing Activities
- -105.46
- Net Changein Cash
- 3.82
- Period
- 2023-06-30
- Total Revenue
- 661.11
- Selling/ General/ Admin Expenses Total
- 25.47
- Depreciation/ Amortization
- 12.6
- Other Operating Expenses Total
- 105.21
- Total Operating Expense
- 589.63
- Operating Income
- 71.48
- Net Income Before Taxes
- 63.53
- Net Income
- 47.84
- Diluted Normalized EPS
- 5.18
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 742.41
- Selling/ General/ Admin Expenses Total
- 25.46
- Depreciation/ Amortization
- 12.5
- Other Operating Expenses Total
- 107.9
- Total Operating Expense
- 661.38
- Operating Income
- 81.03
- Net Income Before Taxes
- 73.28
- Net Income
- 56.09
- Diluted Normalized EPS
- 6.06
- Period
- 2023-03-31
- Total Assets
- 2421.4
- Total Liabilities
- 1228.96
- Total Equity
- 1192.43
- Tangible Book Valueper Share Common Eq
- 128.69
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 134.2
- Cashfrom Investing Activities
- -163.97
- Cashfrom Financing Activities
- 16.54
- Net Changein Cash
- -13.23
- Period
- 2022-12-31
- Total Revenue
- 663.96
- Selling/ General/ Admin Expenses Total
- 23.68
- Depreciation/ Amortization
- 12.62
- Other Operating Expenses Total
- 106.73
- Total Operating Expense
- 605.94
- Operating Income
- 58.02
- Net Income Before Taxes
- 49.68
- Net Income
- 36.69
- Diluted Normalized EPS
- 3.96
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Aarti Drugs Technical
Moving Average
SMA
- 5 Day360.56
- 10 Day352.56
- 20 Day345.82
- 50 Day360.48
- 100 Day398.07
- 300 Day458.03
Aarti Drugs Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Dishman Carbogen Amcis
- 202.95
- -2.2
- -1.07
- 307.8
- 132.75
- 3186.58
- Morepen Laboratories
- 63.1
- 4.28
- 7.28
- 100.8
- 41.66
- 3457.58
- Aarti Drugs
- 354.05
- 3.35
- 0.96
- 634.9
- 312.5
- 3232.8
- Panacea Biotec
- 533
- 14.3
- 2.76
- 549.05
- 112.7
- 3264.67
- Suven Life Sciences
- 133.4
- -2.5
- -1.84
- 169
- 83.27
- 2906.96
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Dishman Carbogen Amcis
- -
- 0.57
- -0.61
- -1.54
- Morepen Laboratories
- 31.27
- 3.55
- 14.17
- 5.49
- Aarti Drugs
- 18.8
- 2.52
- 20.49
- 8.25
- Panacea Biotec
- -
- 3.79
- 31.02
- 24.87
- Suven Life Sciences
- -
- 10.98
- -52.35
- -787.61
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-Jan-25
- Quarterly Results & Interim Dividend
- 24-Oct-24
- Quarterly Results
- 26-Aug-24
- Buy Back of Shares
- 26-Jul-24
- Quarterly Results
- 03-May-24
- Audited Results
- 24-Jan-24
- Quarterly Results & Interim Dividend
- 19-Oct-23
- Quarterly Results
- 21-Jul-23
- Quarterly Results & Buy Back
- 29-Apr-23
- Audited Results
- 27-Jan-23
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 20-Sept-24
- 26-Jul-24
- AGM
- 26-Sept-23
- 29-Apr-23
- AGM
- 04-Aug-22
- 11-Jul-22
- AGM
- 04-Sept-21
- 11-Aug-21
- AGM
- -
- 26-Aug-24
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-Jan-25
- 04-Feb-25
- 04-Feb-25
- 1
- 24-Jan-24
- 06-Feb-24
- 06-Feb-24
- 1
- 27-Jan-23
- 08-Feb-23
- 08-Feb-23
- 1
- 31-Jan-22
- 10-Feb-22
- 09-Feb-22
- 1


